Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8% – What’s Next?
by Amy Steele · The Cerbat GemCapricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) shares dropped 7.8% during trading on Monday . The stock traded as low as $25.74 and last traded at $26.10. Approximately 979,552 shares traded hands during trading, a decline of 0% from the average daily volume of 981,953 shares. The stock had previously closed at $28.31.
Analyst Ratings Changes
CAPR has been the subject of a number of recent research reports. UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a report on Monday, December 15th. Wall Street Zen raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Maxim Group boosted their target price on Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. B. Riley reaffirmed a “buy” rating and set a $50.00 target price (up previously from $21.00) on shares of Capricor Therapeutics in a research report on Monday, December 15th. Finally, Industrial Alliance Securities set a $48.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $40.82.
Check Out Our Latest Stock Report on Capricor Therapeutics
Capricor Therapeutics Stock Performance
The company has a 50-day simple moving average of $16.05 and a 200-day simple moving average of $10.51. The stock has a market cap of $1.13 billion, a P/E ratio of -13.78 and a beta of 0.22.
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). As a group, sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.
Institutional Trading of Capricor Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in shares of Capricor Therapeutics by 6.8% during the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after purchasing an additional 61,701 shares during the period. Woodline Partners LP increased its stake in shares of Capricor Therapeutics by 15.8% in the 1st quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after acquiring an additional 99,384 shares during the last quarter. Pier Capital LLC raised its position in shares of Capricor Therapeutics by 35.0% in the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after acquiring an additional 128,837 shares during the period. Octagon Capital Advisors LP acquired a new stake in shares of Capricor Therapeutics in the 1st quarter valued at approximately $4,270,000. Finally, Goldman Sachs Group Inc. boosted its stake in Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.